http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 30 Jun 2026 08:02:30 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Board+Changes/Quince+Therapeutics+forms+pulmonary+medicine+advisory+board+for+LAM-001/26709971.html <p>Quince Therapeutics, Inc. (Nasdaq: QNCX) announced the formation of a Scientific Advisory Board (SAB) comprised of clinicians in pulmonary medicine to support the development of LAM-001, an inhaled formulation of rapamycin, according to a company statement.</p> <p>The SAB will focus on advancing LAM-001 across three pulmonary indications: pulmonary hypertension associated with interstitial lung disease (PH-ILD), bronchiolitis obliterans syndrome post lung transplant (BOS), and sarcoidosis associated pulmonary hypertension (SAPH).</p> <p>Paul Yu, M.D., Ph.D., Director of the Cardiovascular Research Center at Massachusetts General Hospital and Associate Professor of Medicine at Harvard Medical School, will serve as SAB chairman. Additional members include Aaron Waxman, M.D., http://www.streetinsider.com/Board+Changes/Quince+Therapeutics+forms+pulmonary+medicine+advisory+board+for+LAM-001/26709971.html Tue, 30 Jun 2026 08:02:30 -0400 A.01380988 A.02242875 A.06822034 A.19655944 A.27952506 A.35954321 A.40221050 A.50216920 A.60012014 O.00638181 O.02019993 O.03307993 O.05849870 O.20026344 O.20042365 O.20737027 O.20738343 O.37557959 O.56853832 QNCX http://www.streetinsider.com/Board+Changes/Quince+Therapeutics+forms+pulmonary+medicine+advisory+board+for+LAM-001/26709971.html <p>Quince Therapeutics, Inc. (Nasdaq: QNCX) announced the formation of a Scientific Advisory Board (SAB) comprised of clinicians in pulmonary medicine to support the development of LAM-001, an inhaled formulation of rapamycin, according to a company statement.</p> <p>The SAB will focus on advancing LAM-001 across three pulmonary indications: pulmonary hypertension associated with interstitial lung disease (PH-ILD), bronchiolitis obliterans syndrome post lung transplant (BOS), and sarcoidosis associated pulmonary hypertension (SAPH).</p> <p>Paul Yu, M.D., Ph.D., Director of the Cardiovascular Research Center at Massachusetts General Hospital and Associate Professor of Medicine at Harvard Medical School, will serve as SAB chairman. Additional members include Aaron Waxman, M.D., http://www.streetinsider.com/Board+Changes/Quince+Therapeutics+forms+pulmonary+medicine+advisory+board+for+LAM-001/26709971.html Tue, 30 Jun 2026 08:02:30 -0400 A.01380988 A.02242875 A.06822034 A.19655944 A.27952506 A.35954321 A.40221050 A.50216920 A.60012014 O.00638181 O.02019993 O.03307993 O.05849870 O.20026344 O.20042365 O.20737027 O.20738343 O.37557959 O.56853832 QNCX http://www.streetinsider.com/Board+Changes/Quince+Therapeutics+forms+pulmonary+medicine+advisory+board+for+LAM-001/26709971.html <p>Quince Therapeutics, Inc. (Nasdaq: QNCX) announced the formation of a Scientific Advisory Board (SAB) comprised of clinicians in pulmonary medicine to support the development of LAM-001, an inhaled formulation of rapamycin, according to a company statement.</p> <p>The SAB will focus on advancing LAM-001 across three pulmonary indications: pulmonary hypertension associated with interstitial lung disease (PH-ILD), bronchiolitis obliterans syndrome post lung transplant (BOS), and sarcoidosis associated pulmonary hypertension (SAPH).</p> <p>Paul Yu, M.D., Ph.D., Director of the Cardiovascular Research Center at Massachusetts General Hospital and Associate Professor of Medicine at Harvard Medical School, will serve as SAB chairman. Additional members include Aaron Waxman, M.D., http://www.streetinsider.com/Board+Changes/Quince+Therapeutics+forms+pulmonary+medicine+advisory+board+for+LAM-001/26709971.html Tue, 30 Jun 2026 08:02:30 -0400 A.01380988 A.02242875 A.06822034 A.19655944 A.27952506 A.35954321 A.40221050 A.50216920 A.60012014 O.00638181 O.02019993 O.03307993 O.05849870 O.20026344 O.20042365 O.20737027 O.20738343 O.37557959 O.56853832 QNCX http://www.streetinsider.com/Board+Changes/Quince+Therapeutics+forms+pulmonary+medicine+advisory+board+for+LAM-001/26709971.html <p>Quince Therapeutics, Inc. (Nasdaq: QNCX) announced the formation of a Scientific Advisory Board (SAB) comprised of clinicians in pulmonary medicine to support the development of LAM-001, an inhaled formulation of rapamycin, according to a company statement.</p> <p>The SAB will focus on advancing LAM-001 across three pulmonary indications: pulmonary hypertension associated with interstitial lung disease (PH-ILD), bronchiolitis obliterans syndrome post lung transplant (BOS), and sarcoidosis associated pulmonary hypertension (SAPH).</p> <p>Paul Yu, M.D., Ph.D., Director of the Cardiovascular Research Center at Massachusetts General Hospital and Associate Professor of Medicine at Harvard Medical School, will serve as SAB chairman. Additional members include Aaron Waxman, M.D., http://www.streetinsider.com/Board+Changes/Quince+Therapeutics+forms+pulmonary+medicine+advisory+board+for+LAM-001/26709971.html Tue, 30 Jun 2026 08:02:30 -0400 A.01380988 A.02242875 A.06822034 A.19655944 A.27952506 A.35954321 A.40221050 A.50216920 A.60012014 O.00638181 O.02019993 O.03307993 O.05849870 O.20026344 O.20042365 O.20737027 O.20738343 O.37557959 O.56853832 QNCX http://www.streetinsider.com/Board+Changes/Quince+Therapeutics+forms+pulmonary+medicine+advisory+board+for+LAM-001/26709971.html <p>Quince Therapeutics, Inc. (Nasdaq: QNCX) announced the formation of a Scientific Advisory Board (SAB) comprised of clinicians in pulmonary medicine to support the development of LAM-001, an inhaled formulation of rapamycin, according to a company statement.</p> <p>The SAB will focus on advancing LAM-001 across three pulmonary indications: pulmonary hypertension associated with interstitial lung disease (PH-ILD), bronchiolitis obliterans syndrome post lung transplant (BOS), and sarcoidosis associated pulmonary hypertension (SAPH).</p> <p>Paul Yu, M.D., Ph.D., Director of the Cardiovascular Research Center at Massachusetts General Hospital and Associate Professor of Medicine at Harvard Medical School, will serve as SAB chairman. Additional members include Aaron Waxman, M.D., http://www.streetinsider.com/Board+Changes/Quince+Therapeutics+forms+pulmonary+medicine+advisory+board+for+LAM-001/26709971.html Tue, 30 Jun 2026 08:02:30 -0400 A.01380988 A.02242875 A.06822034 A.19655944 A.27952506 A.35954321 A.40221050 A.50216920 A.60012014 O.00638181 O.02019993 O.03307993 O.05849870 O.20026344 O.20042365 O.20737027 O.20738343 O.37557959 O.56853832 QNCX http://www.streetinsider.com/Board+Changes/Quince+Therapeutics+forms+pulmonary+medicine+advisory+board+for+LAM-001/26709971.html <p>Quince Therapeutics, Inc. (Nasdaq: QNCX) announced the formation of a Scientific Advisory Board (SAB) comprised of clinicians in pulmonary medicine to support the development of LAM-001, an inhaled formulation of rapamycin, according to a company statement.</p> <p>The SAB will focus on advancing LAM-001 across three pulmonary indications: pulmonary hypertension associated with interstitial lung disease (PH-ILD), bronchiolitis obliterans syndrome post lung transplant (BOS), and sarcoidosis associated pulmonary hypertension (SAPH).</p> <p>Paul Yu, M.D., Ph.D., Director of the Cardiovascular Research Center at Massachusetts General Hospital and Associate Professor of Medicine at Harvard Medical School, will serve as SAB chairman. Additional members include Aaron Waxman, M.D., http://www.streetinsider.com/Board+Changes/Quince+Therapeutics+forms+pulmonary+medicine+advisory+board+for+LAM-001/26709971.html Tue, 30 Jun 2026 08:02:30 -0400 A.01380988 A.02242875 A.06822034 A.19655944 A.27952506 A.35954321 A.40221050 A.50216920 A.60012014 O.00638181 O.02019993 O.03307993 O.05849870 O.20026344 O.20042365 O.20737027 O.20738343 O.37557959 O.56853832 QNCX http://www.streetinsider.com/Board+Changes/Quince+Therapeutics+forms+pulmonary+medicine+advisory+board+for+LAM-001/26709971.html <p>Quince Therapeutics, Inc. (Nasdaq: QNCX) announced the formation of a Scientific Advisory Board (SAB) comprised of clinicians in pulmonary medicine to support the development of LAM-001, an inhaled formulation of rapamycin, according to a company statement.</p> <p>The SAB will focus on advancing LAM-001 across three pulmonary indications: pulmonary hypertension associated with interstitial lung disease (PH-ILD), bronchiolitis obliterans syndrome post lung transplant (BOS), and sarcoidosis associated pulmonary hypertension (SAPH).</p> <p>Paul Yu, M.D., Ph.D., Director of the Cardiovascular Research Center at Massachusetts General Hospital and Associate Professor of Medicine at Harvard Medical School, will serve as SAB chairman. Additional members include Aaron Waxman, M.D., http://www.streetinsider.com/Board+Changes/Quince+Therapeutics+forms+pulmonary+medicine+advisory+board+for+LAM-001/26709971.html Tue, 30 Jun 2026 08:02:30 -0400 A.01380988 A.02242875 A.06822034 A.19655944 A.27952506 A.35954321 A.40221050 A.50216920 A.60012014 O.00638181 O.02019993 O.03307993 O.05849870 O.20026344 O.20042365 O.20737027 O.20738343 O.37557959 O.56853832 QNCX http://www.streetinsider.com/Board+Changes/Quince+Therapeutics+forms+pulmonary+medicine+advisory+board+for+LAM-001/26709971.html <p>Quince Therapeutics, Inc. (Nasdaq: QNCX) announced the formation of a Scientific Advisory Board (SAB) comprised of clinicians in pulmonary medicine to support the development of LAM-001, an inhaled formulation of rapamycin, according to a company statement.</p> <p>The SAB will focus on advancing LAM-001 across three pulmonary indications: pulmonary hypertension associated with interstitial lung disease (PH-ILD), bronchiolitis obliterans syndrome post lung transplant (BOS), and sarcoidosis associated pulmonary hypertension (SAPH).</p> <p>Paul Yu, M.D., Ph.D., Director of the Cardiovascular Research Center at Massachusetts General Hospital and Associate Professor of Medicine at Harvard Medical School, will serve as SAB chairman. Additional members include Aaron Waxman, M.D., http://www.streetinsider.com/Board+Changes/Quince+Therapeutics+forms+pulmonary+medicine+advisory+board+for+LAM-001/26709971.html Tue, 30 Jun 2026 08:02:30 -0400 A.01380988 A.02242875 A.06822034 A.19655944 A.27952506 A.35954321 A.40221050 A.50216920 A.60012014 O.00638181 O.02019993 O.03307993 O.05849870 O.20026344 O.20042365 O.20737027 O.20738343 O.37557959 O.56853832 QNCX http://www.streetinsider.com/Board+Changes/Quince+Therapeutics+forms+pulmonary+medicine+advisory+board+for+LAM-001/26709971.html <p>Quince Therapeutics, Inc. (Nasdaq: QNCX) announced the formation of a Scientific Advisory Board (SAB) comprised of clinicians in pulmonary medicine to support the development of LAM-001, an inhaled formulation of rapamycin, according to a company statement.</p> <p>The SAB will focus on advancing LAM-001 across three pulmonary indications: pulmonary hypertension associated with interstitial lung disease (PH-ILD), bronchiolitis obliterans syndrome post lung transplant (BOS), and sarcoidosis associated pulmonary hypertension (SAPH).</p> <p>Paul Yu, M.D., Ph.D., Director of the Cardiovascular Research Center at Massachusetts General Hospital and Associate Professor of Medicine at Harvard Medical School, will serve as SAB chairman. Additional members include Aaron Waxman, M.D., http://www.streetinsider.com/Board+Changes/Quince+Therapeutics+forms+pulmonary+medicine+advisory+board+for+LAM-001/26709971.html Tue, 30 Jun 2026 08:02:30 -0400 A.01380988 A.02242875 A.06822034 A.19655944 A.27952506 A.35954321 A.40221050 A.50216920 A.60012014 O.00638181 O.02019993 O.03307993 O.05849870 O.20026344 O.20042365 O.20737027 O.20738343 O.37557959 O.56853832 QNCX http://www.streetinsider.com/Board+Changes/Quince+Therapeutics+forms+pulmonary+medicine+advisory+board+for+LAM-001/26709971.html <p>Quince Therapeutics, Inc. (Nasdaq: QNCX) announced the formation of a Scientific Advisory Board (SAB) comprised of clinicians in pulmonary medicine to support the development of LAM-001, an inhaled formulation of rapamycin, according to a company statement.</p> <p>The SAB will focus on advancing LAM-001 across three pulmonary indications: pulmonary hypertension associated with interstitial lung disease (PH-ILD), bronchiolitis obliterans syndrome post lung transplant (BOS), and sarcoidosis associated pulmonary hypertension (SAPH).</p> <p>Paul Yu, M.D., Ph.D., Director of the Cardiovascular Research Center at Massachusetts General Hospital and Associate Professor of Medicine at Harvard Medical School, will serve as SAB chairman. Additional members include Aaron Waxman, M.D., http://www.streetinsider.com/Board+Changes/Quince+Therapeutics+forms+pulmonary+medicine+advisory+board+for+LAM-001/26709971.html Tue, 30 Jun 2026 08:02:30 -0400 A.01380988 A.02242875 A.06822034 A.19655944 A.27952506 A.35954321 A.40221050 A.50216920 A.60012014 O.00638181 O.02019993 O.03307993 O.05849870 O.20026344 O.20042365 O.20737027 O.20738343 O.37557959 O.56853832 QNCX http://www.streetinsider.com/Board+Changes/Quince+Therapeutics+forms+pulmonary+medicine+advisory+board+for+LAM-001/26709971.html <p>Quince Therapeutics, Inc. (Nasdaq: QNCX) announced the formation of a Scientific Advisory Board (SAB) comprised of clinicians in pulmonary medicine to support the development of LAM-001, an inhaled formulation of rapamycin, according to a company statement.</p> <p>The SAB will focus on advancing LAM-001 across three pulmonary indications: pulmonary hypertension associated with interstitial lung disease (PH-ILD), bronchiolitis obliterans syndrome post lung transplant (BOS), and sarcoidosis associated pulmonary hypertension (SAPH).</p> <p>Paul Yu, M.D., Ph.D., Director of the Cardiovascular Research Center at Massachusetts General Hospital and Associate Professor of Medicine at Harvard Medical School, will serve as SAB chairman. Additional members include Aaron Waxman, M.D., http://www.streetinsider.com/Board+Changes/Quince+Therapeutics+forms+pulmonary+medicine+advisory+board+for+LAM-001/26709971.html Tue, 30 Jun 2026 08:02:30 -0400 A.01380988 A.02242875 A.06822034 A.19655944 A.27952506 A.35954321 A.40221050 A.50216920 A.60012014 O.00638181 O.02019993 O.03307993 O.05849870 O.20026344 O.20042365 O.20737027 O.20738343 O.37557959 O.56853832 QNCX http://www.streetinsider.com/Board+Changes/Quince+Therapeutics+forms+pulmonary+medicine+advisory+board+for+LAM-001/26709971.html <p>Quince Therapeutics, Inc. (Nasdaq: QNCX) announced the formation of a Scientific Advisory Board (SAB) comprised of clinicians in pulmonary medicine to support the development of LAM-001, an inhaled formulation of rapamycin, according to a company statement.</p> <p>The SAB will focus on advancing LAM-001 across three pulmonary indications: pulmonary hypertension associated with interstitial lung disease (PH-ILD), bronchiolitis obliterans syndrome post lung transplant (BOS), and sarcoidosis associated pulmonary hypertension (SAPH).</p> <p>Paul Yu, M.D., Ph.D., Director of the Cardiovascular Research Center at Massachusetts General Hospital and Associate Professor of Medicine at Harvard Medical School, will serve as SAB chairman. Additional members include Aaron Waxman, M.D., http://www.streetinsider.com/Board+Changes/Quince+Therapeutics+forms+pulmonary+medicine+advisory+board+for+LAM-001/26709971.html Tue, 30 Jun 2026 08:02:30 -0400 A.01380988 A.02242875 A.06822034 A.19655944 A.27952506 A.35954321 A.40221050 A.50216920 A.60012014 O.00638181 O.02019993 O.03307993 O.05849870 O.20026344 O.20042365 O.20737027 O.20738343 O.37557959 O.56853832 QNCX http://www.streetinsider.com/Board+Changes/Quince+Therapeutics+forms+pulmonary+medicine+advisory+board+for+LAM-001/26709971.html <p>Quince Therapeutics, Inc. (Nasdaq: QNCX) announced the formation of a Scientific Advisory Board (SAB) comprised of clinicians in pulmonary medicine to support the development of LAM-001, an inhaled formulation of rapamycin, according to a company statement.</p> <p>The SAB will focus on advancing LAM-001 across three pulmonary indications: pulmonary hypertension associated with interstitial lung disease (PH-ILD), bronchiolitis obliterans syndrome post lung transplant (BOS), and sarcoidosis associated pulmonary hypertension (SAPH).</p> <p>Paul Yu, M.D., Ph.D., Director of the Cardiovascular Research Center at Massachusetts General Hospital and Associate Professor of Medicine at Harvard Medical School, will serve as SAB chairman. Additional members include Aaron Waxman, M.D., http://www.streetinsider.com/Board+Changes/Quince+Therapeutics+forms+pulmonary+medicine+advisory+board+for+LAM-001/26709971.html Tue, 30 Jun 2026 08:02:30 -0400 A.01380988 A.02242875 A.06822034 A.19655944 A.27952506 A.35954321 A.40221050 A.50216920 A.60012014 O.00638181 O.02019993 O.03307993 O.05849870 O.20026344 O.20042365 O.20737027 O.20738343 O.37557959 O.56853832 QNCX http://www.streetinsider.com/Board+Changes/Quince+Therapeutics+forms+pulmonary+medicine+advisory+board+for+LAM-001/26709971.html <p>Quince Therapeutics, Inc. (Nasdaq: QNCX) announced the formation of a Scientific Advisory Board (SAB) comprised of clinicians in pulmonary medicine to support the development of LAM-001, an inhaled formulation of rapamycin, according to a company statement.</p> <p>The SAB will focus on advancing LAM-001 across three pulmonary indications: pulmonary hypertension associated with interstitial lung disease (PH-ILD), bronchiolitis obliterans syndrome post lung transplant (BOS), and sarcoidosis associated pulmonary hypertension (SAPH).</p> <p>Paul Yu, M.D., Ph.D., Director of the Cardiovascular Research Center at Massachusetts General Hospital and Associate Professor of Medicine at Harvard Medical School, will serve as SAB chairman. Additional members include Aaron Waxman, M.D., http://www.streetinsider.com/Board+Changes/Quince+Therapeutics+forms+pulmonary+medicine+advisory+board+for+LAM-001/26709971.html Tue, 30 Jun 2026 08:02:30 -0400 A.01380988 A.02242875 A.06822034 A.19655944 A.27952506 A.35954321 A.40221050 A.50216920 A.60012014 O.00638181 O.02019993 O.03307993 O.05849870 O.20026344 O.20042365 O.20737027 O.20738343 O.37557959 O.56853832 QNCX http://www.streetinsider.com/Board+Changes/Quince+Therapeutics+forms+pulmonary+medicine+advisory+board+for+LAM-001/26709971.html <p>Quince Therapeutics, Inc. (Nasdaq: QNCX) announced the formation of a Scientific Advisory Board (SAB) comprised of clinicians in pulmonary medicine to support the development of LAM-001, an inhaled formulation of rapamycin, according to a company statement.</p> <p>The SAB will focus on advancing LAM-001 across three pulmonary indications: pulmonary hypertension associated with interstitial lung disease (PH-ILD), bronchiolitis obliterans syndrome post lung transplant (BOS), and sarcoidosis associated pulmonary hypertension (SAPH).</p> <p>Paul Yu, M.D., Ph.D., Director of the Cardiovascular Research Center at Massachusetts General Hospital and Associate Professor of Medicine at Harvard Medical School, will serve as SAB chairman. Additional members include Aaron Waxman, M.D., http://www.streetinsider.com/Board+Changes/Quince+Therapeutics+forms+pulmonary+medicine+advisory+board+for+LAM-001/26709971.html Tue, 30 Jun 2026 08:02:30 -0400 A.01380988 A.02242875 A.06822034 A.19655944 A.27952506 A.35954321 A.40221050 A.50216920 A.60012014 O.00638181 O.02019993 O.03307993 O.05849870 O.20026344 O.20042365 O.20737027 O.20738343 O.37557959 O.56853832 QNCX http://www.streetinsider.com/Board+Changes/Quince+Therapeutics+forms+pulmonary+medicine+advisory+board+for+LAM-001/26709971.html <p>Quince Therapeutics, Inc. (Nasdaq: QNCX) announced the formation of a Scientific Advisory Board (SAB) comprised of clinicians in pulmonary medicine to support the development of LAM-001, an inhaled formulation of rapamycin, according to a company statement.</p> <p>The SAB will focus on advancing LAM-001 across three pulmonary indications: pulmonary hypertension associated with interstitial lung disease (PH-ILD), bronchiolitis obliterans syndrome post lung transplant (BOS), and sarcoidosis associated pulmonary hypertension (SAPH).</p> <p>Paul Yu, M.D., Ph.D., Director of the Cardiovascular Research Center at Massachusetts General Hospital and Associate Professor of Medicine at Harvard Medical School, will serve as SAB chairman. Additional members include Aaron Waxman, M.D., http://www.streetinsider.com/Board+Changes/Quince+Therapeutics+forms+pulmonary+medicine+advisory+board+for+LAM-001/26709971.html Tue, 30 Jun 2026 08:02:30 -0400 A.01380988 A.02242875 A.06822034 A.19655944 A.27952506 A.35954321 A.40221050 A.50216920 A.60012014 O.00638181 O.02019993 O.03307993 O.05849870 O.20026344 O.20042365 O.20737027 O.20738343 O.37557959 O.56853832 QNCX http://www.streetinsider.com/Board+Changes/Quince+Therapeutics+forms+pulmonary+medicine+advisory+board+for+LAM-001/26709971.html <p>Quince Therapeutics, Inc. (Nasdaq: QNCX) announced the formation of a Scientific Advisory Board (SAB) comprised of clinicians in pulmonary medicine to support the development of LAM-001, an inhaled formulation of rapamycin, according to a company statement.</p> <p>The SAB will focus on advancing LAM-001 across three pulmonary indications: pulmonary hypertension associated with interstitial lung disease (PH-ILD), bronchiolitis obliterans syndrome post lung transplant (BOS), and sarcoidosis associated pulmonary hypertension (SAPH).</p> <p>Paul Yu, M.D., Ph.D., Director of the Cardiovascular Research Center at Massachusetts General Hospital and Associate Professor of Medicine at Harvard Medical School, will serve as SAB chairman. Additional members include Aaron Waxman, M.D., http://www.streetinsider.com/Board+Changes/Quince+Therapeutics+forms+pulmonary+medicine+advisory+board+for+LAM-001/26709971.html Tue, 30 Jun 2026 08:02:30 -0400 A.01380988 A.02242875 A.06822034 A.19655944 A.27952506 A.35954321 A.40221050 A.50216920 A.60012014 O.00638181 O.02019993 O.03307993 O.05849870 O.20026344 O.20042365 O.20737027 O.20738343 O.37557959 O.56853832 QNCX http://www.streetinsider.com/Board+Changes/Quince+Therapeutics+forms+pulmonary+medicine+advisory+board+for+LAM-001/26709971.html <p>Quince Therapeutics, Inc. (Nasdaq: QNCX) announced the formation of a Scientific Advisory Board (SAB) comprised of clinicians in pulmonary medicine to support the development of LAM-001, an inhaled formulation of rapamycin, according to a company statement.</p> <p>The SAB will focus on advancing LAM-001 across three pulmonary indications: pulmonary hypertension associated with interstitial lung disease (PH-ILD), bronchiolitis obliterans syndrome post lung transplant (BOS), and sarcoidosis associated pulmonary hypertension (SAPH).</p> <p>Paul Yu, M.D., Ph.D., Director of the Cardiovascular Research Center at Massachusetts General Hospital and Associate Professor of Medicine at Harvard Medical School, will serve as SAB chairman. Additional members include Aaron Waxman, M.D., http://www.streetinsider.com/Board+Changes/Quince+Therapeutics+forms+pulmonary+medicine+advisory+board+for+LAM-001/26709971.html Tue, 30 Jun 2026 08:02:30 -0400 A.01380988 A.02242875 A.06822034 A.19655944 A.27952506 A.35954321 A.40221050 A.50216920 A.60012014 O.00638181 O.02019993 O.03307993 O.05849870 O.20026344 O.20042365 O.20737027 O.20738343 O.37557959 O.56853832 QNCX http://www.streetinsider.com/Board+Changes/Quince+Therapeutics+forms+pulmonary+medicine+advisory+board+for+LAM-001/26709971.html <p>Quince Therapeutics, Inc. (Nasdaq: QNCX) announced the formation of a Scientific Advisory Board (SAB) comprised of clinicians in pulmonary medicine to support the development of LAM-001, an inhaled formulation of rapamycin, according to a company statement.</p> <p>The SAB will focus on advancing LAM-001 across three pulmonary indications: pulmonary hypertension associated with interstitial lung disease (PH-ILD), bronchiolitis obliterans syndrome post lung transplant (BOS), and sarcoidosis associated pulmonary hypertension (SAPH).</p> <p>Paul Yu, M.D., Ph.D., Director of the Cardiovascular Research Center at Massachusetts General Hospital and Associate Professor of Medicine at Harvard Medical School, will serve as SAB chairman. Additional members include Aaron Waxman, M.D., http://www.streetinsider.com/Board+Changes/Quince+Therapeutics+forms+pulmonary+medicine+advisory+board+for+LAM-001/26709971.html Tue, 30 Jun 2026 08:02:30 -0400 A.01380988 A.02242875 A.06822034 A.19655944 A.27952506 A.35954321 A.40221050 A.50216920 A.60012014 O.00638181 O.02019993 O.03307993 O.05849870 O.20026344 O.20042365 O.20737027 O.20738343 O.37557959 O.56853832 QNCX http://www.streetinsider.com/Board+Changes/Quince+Therapeutics+forms+pulmonary+medicine+advisory+board+for+LAM-001/26709971.html <p>Quince Therapeutics, Inc. (Nasdaq: QNCX) announced the formation of a Scientific Advisory Board (SAB) comprised of clinicians in pulmonary medicine to support the development of LAM-001, an inhaled formulation of rapamycin, according to a company statement.</p> <p>The SAB will focus on advancing LAM-001 across three pulmonary indications: pulmonary hypertension associated with interstitial lung disease (PH-ILD), bronchiolitis obliterans syndrome post lung transplant (BOS), and sarcoidosis associated pulmonary hypertension (SAPH).</p> <p>Paul Yu, M.D., Ph.D., Director of the Cardiovascular Research Center at Massachusetts General Hospital and Associate Professor of Medicine at Harvard Medical School, will serve as SAB chairman. Additional members include Aaron Waxman, M.D., http://www.streetinsider.com/Board+Changes/Quince+Therapeutics+forms+pulmonary+medicine+advisory+board+for+LAM-001/26709971.html Tue, 30 Jun 2026 08:02:30 -0400 A.01380988 A.02242875 A.06822034 A.19655944 A.27952506 A.35954321 A.40221050 A.50216920 A.60012014 O.00638181 O.02019993 O.03307993 O.05849870 O.20026344 O.20042365 O.20737027 O.20738343 O.37557959 O.56853832 QNCX http://www.streetinsider.com/Press+Releases/Quince+Therapeutics+Appoints+Recognized+Leaders+in+Pulmonary+Medicine+to+Scientific+Advisory+Board/26709892.html <p>SOUTH SAN FRANCISCO, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QNCX), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapies for serious underserved diseases, today announced the formation of a Scientific Advisory Board (SAB) of leading clinicians to support the advancement of LAM-001, an inhaled formulation of rapamycin (mTOR inhibitor) designed to enhance pulmonary delivery and reduce systemic exposure.</p> <p>Comprised of internationally recognized experts in pulmonary medicine, the SAB will be instrumental in progressing the development of LAM-001 across multiple pulmonary indications including pulmonary hypertension associated with interstitial http://www.streetinsider.com/Press+Releases/Quince+Therapeutics+Appoints+Recognized+Leaders+in+Pulmonary+Medicine+to+Scientific+Advisory+Board/26709892.html Tue, 30 Jun 2026 08:00:00 -0400 A.01380988 A.02242875 A.06822034 A.19655944 A.27952506 A.35954321 A.40221050 A.50216920 A.60012014 O.00638181 O.02019993 O.03307993 O.05849870 O.20026344 O.20042365 O.20737027 O.20738343 O.37557959 O.56853832 QNCX http://www.streetinsider.com/Press+Releases/Quince+Therapeutics+Appoints+Recognized+Leaders+in+Pulmonary+Medicine+to+Scientific+Advisory+Board/26709892.html <p>SOUTH SAN FRANCISCO, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QNCX), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapies for serious underserved diseases, today announced the formation of a Scientific Advisory Board (SAB) of leading clinicians to support the advancement of LAM-001, an inhaled formulation of rapamycin (mTOR inhibitor) designed to enhance pulmonary delivery and reduce systemic exposure.</p> <p>Comprised of internationally recognized experts in pulmonary medicine, the SAB will be instrumental in progressing the development of LAM-001 across multiple pulmonary indications including pulmonary hypertension associated with interstitial http://www.streetinsider.com/Press+Releases/Quince+Therapeutics+Appoints+Recognized+Leaders+in+Pulmonary+Medicine+to+Scientific+Advisory+Board/26709892.html Tue, 30 Jun 2026 08:00:00 -0400 A.01380988 A.02242875 A.06822034 A.19655944 A.27952506 A.35954321 A.40221050 A.50216920 A.60012014 O.00638181 O.02019993 O.03307993 O.05849870 O.20026344 O.20042365 O.20737027 O.20738343 O.37557959 O.56853832 QNCX http://www.streetinsider.com/Press+Releases/Quince+Therapeutics+Appoints+Recognized+Leaders+in+Pulmonary+Medicine+to+Scientific+Advisory+Board/26709892.html <p>SOUTH SAN FRANCISCO, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QNCX), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapies for serious underserved diseases, today announced the formation of a Scientific Advisory Board (SAB) of leading clinicians to support the advancement of LAM-001, an inhaled formulation of rapamycin (mTOR inhibitor) designed to enhance pulmonary delivery and reduce systemic exposure.</p> <p>Comprised of internationally recognized experts in pulmonary medicine, the SAB will be instrumental in progressing the development of LAM-001 across multiple pulmonary indications including pulmonary hypertension associated with interstitial http://www.streetinsider.com/Press+Releases/Quince+Therapeutics+Appoints+Recognized+Leaders+in+Pulmonary+Medicine+to+Scientific+Advisory+Board/26709892.html Tue, 30 Jun 2026 08:00:00 -0400 A.01380988 A.02242875 A.06822034 A.19655944 A.27952506 A.35954321 A.40221050 A.50216920 A.60012014 O.00638181 O.02019993 O.03307993 O.05849870 O.20026344 O.20042365 O.20737027 O.20738343 O.37557959 O.56853832 QNCX http://www.streetinsider.com/Press+Releases/Quince+Therapeutics+Appoints+Recognized+Leaders+in+Pulmonary+Medicine+to+Scientific+Advisory+Board/26709892.html <p>SOUTH SAN FRANCISCO, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QNCX), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapies for serious underserved diseases, today announced the formation of a Scientific Advisory Board (SAB) of leading clinicians to support the advancement of LAM-001, an inhaled formulation of rapamycin (mTOR inhibitor) designed to enhance pulmonary delivery and reduce systemic exposure.</p> <p>Comprised of internationally recognized experts in pulmonary medicine, the SAB will be instrumental in progressing the development of LAM-001 across multiple pulmonary indications including pulmonary hypertension associated with interstitial http://www.streetinsider.com/Press+Releases/Quince+Therapeutics+Appoints+Recognized+Leaders+in+Pulmonary+Medicine+to+Scientific+Advisory+Board/26709892.html Tue, 30 Jun 2026 08:00:00 -0400 A.01380988 A.02242875 A.06822034 A.19655944 A.27952506 A.35954321 A.40221050 A.50216920 A.60012014 O.00638181 O.02019993 O.03307993 O.05849870 O.20026344 O.20042365 O.20737027 O.20738343 O.37557959 O.56853832 QNCX http://www.streetinsider.com/Press+Releases/Quince+Therapeutics+Appoints+Recognized+Leaders+in+Pulmonary+Medicine+to+Scientific+Advisory+Board/26709892.html <p>SOUTH SAN FRANCISCO, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QNCX), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapies for serious underserved diseases, today announced the formation of a Scientific Advisory Board (SAB) of leading clinicians to support the advancement of LAM-001, an inhaled formulation of rapamycin (mTOR inhibitor) designed to enhance pulmonary delivery and reduce systemic exposure.</p> <p>Comprised of internationally recognized experts in pulmonary medicine, the SAB will be instrumental in progressing the development of LAM-001 across multiple pulmonary indications including pulmonary hypertension associated with interstitial http://www.streetinsider.com/Press+Releases/Quince+Therapeutics+Appoints+Recognized+Leaders+in+Pulmonary+Medicine+to+Scientific+Advisory+Board/26709892.html Tue, 30 Jun 2026 08:00:00 -0400 A.01380988 A.02242875 A.06822034 A.19655944 A.27952506 A.35954321 A.40221050 A.50216920 A.60012014 O.00638181 O.02019993 O.03307993 O.05849870 O.20026344 O.20042365 O.20737027 O.20738343 O.37557959 O.56853832 QNCX